患有与未患有系统性自身免疫/炎症性风湿病的成人阿片类药物处方:2006-2019年美国全国数据分析
该横断面研究利用2006-2019年美国全国门诊医疗调查数据,比较了患有系统性自身免疫/炎症性风湿病(SARDs)与未患SARDs的成人门诊就诊中阿片类药物处方情况。结果显示,SARDs组阿片类药物处方率(22.53%)高于非SARDs组(9.83%)(aOR 2.65;95%CI 1.68-4.18)。在SARDs就诊中,年龄50-64岁和处方糖皮质激素与阿片类药物处方几率增加相关,而私人保险相对于Medicare与处方几率降低相关。
要点
- SARDs患者门诊就诊中阿片类药物处方率为22.53%,高于非SARDs组的9.83%(aOR 2.65;95%CI 1.68-4.18)。
- 在SARDs就诊中,年龄50-64岁相对于18-49岁与阿片类药物处方几率增加相关(aOR 1.95;95%CI 1.05-3.65)。
- 在SARDs就诊中,处方糖皮质激素与阿片类药物处方几率增加相关(aOR 1.75;95%CI 1.20-2.54),私人保险相对于Medicare与几率降低相关(aOR 0.50;95%CI 0.31-0.82)。
核心结论
- SARDs患者中阿片类药物处方率高于非SARDs患者,需要共同努力确定SARDs中阿片类药物处方的适当性。
研究设计与样本
- 横断面研究,使用2006年至2019年美国全国门诊医疗调查数据,纳入年龄≥18岁、主要诊断为SARDs(包括类风湿关节炎、强直性脊柱炎、银屑病关节炎或系统性红斑狼疮)的成人门诊就诊。
主要发现
- SARDs组阿片类药物处方率为22.53%,非SARDs组为9.83%,调整后比值比(aOR)为2.65(95%CI 1.68-4.18)。
- 在SARDs就诊中,年龄50-64岁相对于18-49岁的aOR为1.95(95%CI 1.05-3.65),处方糖皮质激素的aOR为1.75(95%CI 1.20-2.54),私人保险相对于Medicare的aOR为0.50(95%CI 0.31-0.82)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study compared opioid prescribing among ambulatory visits with systemic autoimmune/inflammatory rheumatic diseases (SARDs) or without and assessed factors associated with opioid prescribing in SARDs. METHODS: This cross-sectional study used the National Ambulatory Medical Care Survey between 2006 and 2019. Adult (≥18 years) visits with a primary diagnosis of SARDs, including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, or systemic lupus erythematosus were included in the study. Opioid prescribing was compared between those with vs without SARDs using multivariable logistic regression accounting for the complex survey design and adjusting for predisposing, enabling, and need factors within Andersen's Behavioral Model of Health Services Use. Another multivariable logistic regression examined the predictors associated with opioid prescribing in SARDs. RESULTS: Annually, an average of 5.20 million (95% confidence interval [CI] 3.58-6.82) visits were made for SARDs, whereas 780.14 million (95% CI 747.56-812.72) visits were made for non-SARDs. The SARDs group was more likely to be prescribed opioids (22.53%) than the non-SARDs group (9.83%) (adjusted odds ratio [aOR] 2.65; 95% CI 1.68-4.18). Among the SARDs visits, patient age from 50 to 64 (aOR 1.95; 95% CI 1.05-3.65 relative to ages 18-49) and prescribing of glucocorticoids (aOR 1.75; 95% CI 1.20-2.54) were associated with an increased odd of opioid prescribing, whereas private insurance relative to Medicare (aOR 0.50; 95% CI 0.31-0.82) was associated with a decreased odds of opioid prescribing. CONCLUSION: Opioid prescribing in SARDs was higher compared to non-SARDs. Concerted efforts are needed to determine the appropriateness of opioid prescribing in SARDs.
引用
- Huang Y, Bruera S, Agarwal SK, et al. Opioid Treatment for Adults With and Without Systemic Autoimmune/Inflammatory Rheumatic Diseases: Analysis of 2006-2019 United States National Data. Arthritis Care Res (Hoboken). 2024. PMID: 38766880. doi:10.1002/acr.25378
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。